All In Biotech

Drug Trial Radar · NCT04103892

A Study of CLE-100 (Oral Esketamine) in Addition to Standard Antidepressant Drug for Major Depressive Disorder - CLEO Study

A Two-Part Study of CLE-100 as an Adjunct Therapy in Subjects With Major Depressive Disorder

Last checked: Nov 19, 2026Latest source record: Oct 14, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 146 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

146

Actual

Start

Sep 5, 2019

Primary completion

Sep 21, 2022

Study completion Oct 5, 2022

Sponsor

Lead sponsor
Clexio Biosciences Ltd.Industry
Sponsor type
Industry
First posted
Sep 26, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The clinical trial is a Phase 2, double-blind, randomized, placebo controlled study in Major Depressive Disorder (MDD) participants currently treated with antidepressant therapy. The objective of the study is to assess CLE-100 for the treatment of MDD in participants currently treated with standard antidepressant therapy.

Conditions

  • Adjunctive Treatment of Major Depressive Disorder

Interventions

  • CLE-100Drug

    1 tablet of CLE-100 administered once daily

  • placeboDrug

    1 tablet of placebo administered once daily

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part B - Change From Baseline in Montgomery-Asberg Depression Rating Scale (MADRS) ScoreTime frame: 29 days

Locations

46 sites in 2 countries. Site status is shown where the registry gives one.

  • Clinical Site 126

    Bentonville, Arkansas

  • Clinical Site 120

    Little Rock, Arkansas

  • Clinical Site 129

    Little Rock, Arkansas

  • Clinical Site 141

    Anaheim, California

  • Clinical Site 115

    Bellflower, California

  • Clinical Site 132

    Lafayette, California

  • Clinical Site 117

    Oakland, California

  • Clinical Site 113

    Oceanside, California

  • Clinical Site 123

    Riverside, California

  • Clinical Site 124

    Santa Ana, California

  • Clinical Site 142

    Santa Rosa, California

  • Clinical Site 112

    Torrance, California

  • Clinical Site 145

    Denver, Colorado

  • Clinical Site 107

    Hialeah, Florida

  • Clinical Site 116

    Miami, Florida

  • Clinical Site 108

    Miami Gardens, Florida

  • Clinical Site 105

    Orlando, Florida

  • Clinical Site 137

    Orlando, Florida

  • Clinical Site 140

    Atlanta, Georgia

  • Clinical Site 104

    Decatur, Georgia

  • Clinical Site 122

    Marietta, Georgia

  • Clinical Site 131

    Baltimore, Maryland

  • Clinical Site 136

    Rockville, Maryland

  • Clinical Site 103

    Boston, Massachusetts

  • Clinical Site 121

    Boston, Massachusetts

  • Clinical Site 151

    Dearborn Heights, Michigan

  • Clinical Site 139

    St Louis, Missouri

  • Clinical Site 125

    Lincoln, Nebraska

  • Clinical Site 110

    Las Vegas, Nevada

  • Clinical Site 101

    Marlton, New Jersey

  • Clinical Site 148

    Toms River, New Jersey

  • Clinical Site 128

    New York, New York

  • Clinical Site 102

    Staten Island, New York

  • Clinical Site 111

    Hickory, North Carolina

  • Clinical Site 143

    Raleigh, North Carolina

  • Clinical Site 138

    Middleburg Heights, Ohio

  • Clinical Site 127

    North Canton, Ohio

  • Clinical Site 106

    Media, Pennsylvania

  • Clinical Site 118

    Philadelphia, Pennsylvania

  • Clinical Site 114

    Fort Worth, Texas

Showing 40 of 46 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.